Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis
Carregando...
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER SOC CLINICAL ONCOLOGY
Citação
JOURNAL OF GLOBAL ONCOLOGY, v.4, 2018
Resumo
Purpose The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain. We evaluated the outcomes of patients with high-risk endometrial cancer treated with adjuvant chemotherapy followed by radiotherapy. Patients and Methods We performed a retrospective analysis of patients with high-risk endometrial cancer (endometrioid histology stages III to IVA or carcinosarcoma, clear cell, or serous histology stages I to IVA) treated with adjuvant carboplatin and paclitaxel, followed by radiotherapy, from 2010 to 2017 at a Brazilian cancer center. The Kaplan-Meier method was used for survival analysis, and prognostic factors were analyzed using the Cox proportional hazards model. Results One hundred forty-six consecutive patients were evaluated. The OS rates were 86.2% at 3 years and 75.4% at 5 years. OS was significantly affected by pelvic lymphadenectomy (P = .001) and positive peritoneal cytology (P < .001). Three- and 5-year disease-free survival (DFS) rates were 78.3% and 69.5%, respectively. The initial site of recurrence was limited to the pelvis in 4.1% of patients, within the abdomen in 1.3%, and extra-abdominal in 11.6%. Patients with grade 1 or 2 endometrioid carcinoma had better prognosis than patients with endometrioid carcinoma grade 3 or nonendometrioid histology (3-year DFS, 93.67% v 68.5%, respectively; P = .0017). Conclusion Adjuvant carboplatin and paclitaxel, followed by radiotherapy, is effective in high-risk endometrial cancer and associated with low rates of pelvic recurrence, which might be explained by the addition of radiotherapy. The high-risk group is heterogeneous, and the benefit of adjuvant treatment in patients with grade 1 or 2 endometrioid carcinoma is less clear. (C) 2018 by American Society of Clinical Oncology
Palavras-chave
Referências
- Bendifallah S, 2017, GYNECOL ONCOL, V144, P107, DOI 10.1016/j.ygyno.2016.10.025
- Colombo N, 2016, ANN ONCOL, V27, P16, DOI 10.1093/annonc/mdv484
- de Boer SM, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5502
- Hogberg T, 2010, EUR J CANCER, V46, P2422, DOI 10.1016/j.ejca.2010.06.002
- Maggi R, 2006, BRIT J CANCER, V95, P266, DOI 10.1038/sj.bjc.6603279
- Matei D, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5505
- Meyer LA, 2015, J CLIN ONCOL, V33, P2908, DOI 10.1200/JCO.2015.62.5459
- Miller D, 2012, GYNECOL ONCOL, V125, P771, DOI 10.1016/j.ygyno.2012.03.034
- Morneau M, 2013, GYNECOL ONCOL, V131, P231, DOI 10.1016/j.ygyno.2013.07.084
- Nomura H, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5503
- Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2
- Randall ME, 2006, J CLIN ONCOL, V24, P36, DOI 10.1200/JCO.2004.00.7617